Tema Etfs LLC Acquires 2,168 Shares of Amgen Inc. $AMGN

Tema Etfs LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 12.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,132 shares of the medical research company’s stock after buying an additional 2,168 shares during the quarter. Tema Etfs LLC’s holdings in Amgen were worth $6,589,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares in the last quarter. Schnieders Capital Management LLC. grew its holdings in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in Amgen during the second quarter valued at about $59,836,000. Finally, Groupe la Francaise purchased a new stake in Amgen in the second quarter worth about $222,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMGN. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Rothschild & Co Redburn boosted their price objective on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Wells Fargo & Company increased their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Argus raised their target price on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Finally, Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Up 0.4%

Shares of AMGN opened at $353.28 on Thursday. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The business has a fifty day moving average of $363.57 and a 200 day moving average of $331.74. The company has a market cap of $190.44 billion, a PE ratio of 24.83, a P/E/G ratio of 3.49 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 EPS. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst/sector endorsements: recent analyst commentary (Zacks) highlights Amgen’s strong drug portfolio and resilience versus sector headwinds, which supports investor sentiment and helps the stock. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Positive Sentiment: Inclusion in buy lists: Amgen appears in a recent “5 Best Pharma Stocks to Invest In Now” roundup, which can attract longer‑term inflows and positive sentiment from retail/institutional investors. 5 Best Pharma Stocks to Invest In Now
• Neutral Sentiment: Brokerage consensus: a recent survey shows AMGN carries an average “Hold” rating from brokerages — not a downgrade but a sign analysts see limited near‑term upside absent new catalysts. Amgen Inc. (NASDAQ:AMGN) Given Average Rating of “Hold” by Brokerages
• Negative Sentiment: Safety alert on Tavneos: the U.S. FDA has flagged multiple cases of drug‑induced liver injury — including deaths — linked to Amgen’s rare‑disease drug Tavneos (76 cases identified). The agency is urging closer monitoring and prompt discontinuation if liver damage is suspected; this poses regulatory, reputational and potential liability risks that could pressure the stock. US FDA warns of liver injury cases tied to Amgen’s rare disease drug FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths
• Negative Sentiment: Biosimilars competition: Teva won FDA approval for a Prolia biosimilar (Ponlimsi) and advanced other biosimilar filings — increased biosimilars activity raises competitive pressure in areas where Amgen has legacy biologics, potentially weighing on future sales. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.